Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Mahindra & Mahindra Ltd (MM:IN) (MAHMF) PT Raised to INR320 at HSBC
- HSBC Downgrades Shriram Finance Ltd (SHFL:IN) to Hold
- UK budget airline easyJet ready to accept $7.3 billion takeover bid from Castlelake
- Strategy reports $8.32B bitcoin loss and sells BTC to fund dividends
- Citi Adds Micron Technology (MU) to 90-Day Upside Catalyst Watch List
Evofem Biosciences (EVFM) Misses Q2 EPS by 54c
August 4, 2020 8:07 AM EDTEvofem Biosciences (NASDAQ: EVFM) reported Q2 EPS of ($0.91), $0.54 worse than the analyst estimate of ($0.37).
Second quarter and recent highlights include:
Received U.S. Food and Drug Administration (FDA) approval of Phexxi (lactic acid, citric acid and potassium bitartrate) for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception; Strengthened the balance sheet with approximately $136 million in gross proceeds from two financing transactions during an incredibly challenging... More